{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:36:26Z","timestamp":1791765386382,"version":"4.3.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40120-025-00739-5","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T07:36:29Z","timestamp":1744443389000},"page":"927-948","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["CILO-CLOP Trial: Cilostazol Versus Clopidogrel in Acute Moderate and Moderate-to-Severe Ischemic Stroke: A Randomized Controlled Multicenter Trial"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0337-349X","authenticated-orcid":false,"given":"Mohamed G.","family":"Zeinhom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ismaiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Fouad Elsayed","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ahmed","family":"Almoataz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek Youssif","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Mohamed Ali","family":"Daabis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossam Mohamed","family":"Refat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Ahmed Mohamed Kamal","family":"Ebied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Abdelwahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Zaki Omar","family":"Akl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad Labib Abdelhamid","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah Ibrahim","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherihan Rezk","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"issue":"5","key":"739_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40263-024-01080-5","volume":"38","author":"MG Zeinhom","year":"2024","unstructured":"Zeinhom MG, Elbassiouny A, Mahmoud A, Sherihan M, Ahmed R. Ticagrelor versus clopidogrel in acute large-vessel ischemic stroke: a randomized controlled single-blinded trial. CNS Drugs. 2024;38(5):387\u201393. https:\/\/doi.org\/10.1007\/s40263-024-01080-5.","journal-title":"CNS Drugs"},{"issue":"2","key":"739_CR2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10072-022-06525-7","volume":"44","author":"HM Aref","year":"2023","unstructured":"Aref HM, El-Khawas H, Elbassiouny A, Shokri HM, Zeinhom MG, Roushdy TM. A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke. Neurol Sci. 2023;44(2):765\u201371. https:\/\/doi.org\/10.1007\/s10072-022-06525-7.","journal-title":"Neurol Sci"},{"issue":"12","key":"739_CR3","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","volume":"50","author":"WJ Powers","year":"2019","unstructured":"Powers WJ, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke. Stroke. 2019;50(12):e344\u2013418. https:\/\/doi.org\/10.1161\/STR.0000000000000211.","journal-title":"Stroke"},{"issue":"1","key":"739_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-56067-5","volume":"14","author":"MG Zeinhom","year":"2024","unstructured":"Zeinhom MG, et al. Predictors of the unfavorable outcomes in acute ischemic stroke patients treated with alteplase, a multi-center randomized trial. Sci Rep. 2024;14(1):1\u20139. https:\/\/doi.org\/10.1038\/s41598-024-56067-5.","journal-title":"Sci Rep"},{"issue":"6","key":"739_CR5","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1161\/STROKEAHA.108.540112","volume":"40","author":"KK Andersen","year":"2009","unstructured":"Andersen KK, Olsen TS, Dehlendorff C, Kammersgaard LP. Hemorrhagic and ischemic strokes compared. Stroke. 2009;40(6):2068\u201372. https:\/\/doi.org\/10.1161\/STROKEAHA.108.540112.","journal-title":"Stroke"},{"key":"739_CR6","first-page":"215","volume":"25","author":"T Tani","year":"1992","unstructured":"Tani T, Sakurai K, Kimura Y, Ishikawa T, Hidaka H. Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells. Adv Second Messenger Phosphoprotein Res. 1992;25:215\u201327.","journal-title":"Adv Second Messenger Phosphoprotein Res"},{"key":"739_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/978-3-642-29423-5_9","volume":"210","author":"MT Rondina","year":"2012","unstructured":"Rondina MT, Weyrich AS. Targeting phosphodiesterases in anti-platelet therapy. Handb Exp Pharmacol. 2012;210:225\u201338. https:\/\/doi.org\/10.1007\/978-3-642-29423-5_9.","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"739_CR8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/20009666.2019.1644915","volume":"9","author":"C Volney","year":"2019","unstructured":"Volney C, Collins A, Adams S. Ticagrelor versus clopidogrel in the management of acute myocardial infarction. J Commun Hosp Intern Med Perspect. 2019;9(4):314\u20138. https:\/\/doi.org\/10.1080\/20009666.2019.1644915.","journal-title":"J Commun Hosp Intern Med Perspect"},{"issue":"4","key":"739_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5114\/pwki.2015.55596","volume":"11","author":"MP Winter","year":"2015","unstructured":"Winter MP, Kozi\u0144ski M, Kubica J, Aradi D, Siller-Matula JM. Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postep w Kardiol Interwencyjnej. 2015;11(4):259\u201380. https:\/\/doi.org\/10.5114\/pwki.2015.55596.","journal-title":"Postep w Kardiol Interwencyjnej"},{"issue":"8","key":"739_CR10","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1161\/STROKEAHA.120.029454","volume":"51","author":"C McHutchison","year":"2020","unstructured":"McHutchison C, et al. Cilostazol for secondary prevention of stroke and cognitive decline: systematic review and meta-analysis. Stroke. 2020;51(8):2374\u201385. https:\/\/doi.org\/10.1161\/STROKEAHA.120.029454.","journal-title":"Stroke"},{"issue":"1","key":"739_CR11","doi-asserted-by":"publisher","first-page":"29822","DOI":"10.1038\/s41598-024-76189-0","volume":"14","author":"MG Zeinhom","year":"2024","unstructured":"Zeinhom MG, et al. A multicenter trial on the predictors of different subtypes of hemorrhagic infarction after thrombolysis. Sci Rep. 2024;14(1):29822. https:\/\/doi.org\/10.1038\/s41598-024-76189-0.","journal-title":"Sci Rep"},{"key":"739_CR12","unstructured":"Julie Fussner CV. Assessing stroke\u2014scores & scales. Am. Stroke Assoc., pp. 1\u201323; 2019. https:\/\/www.heart.org\/-\/media\/files\/affiliates\/gra\/gra-qsi\/2019-scbc-presentations\/5-assessing-stroke-scores-scales-v2.pdf?la=en"},{"issue":"1","key":"739_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12911-019-1010-x","volume":"20","author":"E Kogan","year":"2020","unstructured":"Kogan E, Twyman K, Heap J, Milentijevic D, Lin JH, Alberts M. Assessing stroke severity using electronic health record data: a machine learning approach. BMC Med Inform Decis Mak. 2020;20(1):8. https:\/\/doi.org\/10.1186\/s12911-019-1010-x.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"739_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000518786","volume":"85","author":"MG Zeinhom","year":"2022","unstructured":"Zeinhom MG, Aref HM, El-Khawas H, Roushdy TM, Shokri HM, Elbassiouny A. A pilot study of the ticagrelor role in ischemic stroke secondary prevention. Eur Neurol. 2022;85(1):50\u20135. https:\/\/doi.org\/10.1159\/000518786.","journal-title":"Eur Neurol"},{"issue":"1","key":"739_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.121.010409","volume":"15","author":"S Matsuoka","year":"2022","unstructured":"Matsuoka S, et al. Age modified relationship between modifiable risk factors and the risk of atrial fibrillation. Circ Arrhythmia Electrophysiol. 2022;15(1): e010409. https:\/\/doi.org\/10.1161\/CIRCEP.121.010409.","journal-title":"Circ Arrhythmia Electrophysiol"},{"issue":"3","key":"739_CR16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1001\/jama.2022.23924","volume":"329","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, et al. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA. 2023;329(3):214\u201323. https:\/\/doi.org\/10.1001\/jama.2022.23924.","journal-title":"JAMA"},{"issue":"23","key":"739_CR17","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1161\/CIRCULATIONAHA.113.003284","volume":"127","author":"T Zeller","year":"2013","unstructured":"Zeller T, Trenk D. Cilostazol. Circulation. 2013;127(23):2261\u20133. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.003284.","journal-title":"Circulation"},{"issue":"4","key":"739_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","volume":"13","author":"RG Hart","year":"2014","unstructured":"Hart RG, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429\u201338. https:\/\/doi.org\/10.1016\/S1474-4422(13)70310-7.","journal-title":"Lancet Neurol"},{"issue":"25","key":"739_CR19","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.117.030509","volume":"136","author":"G Ntaios","year":"2017","unstructured":"Ntaios G, Hart RG. Embolic stroke. Circulation. 2017;136(25):2403\u20135. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030509.","journal-title":"Circulation"},{"issue":"5","key":"739_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612.","journal-title":"Eur Heart J"},{"issue":"10","key":"739_CR21","doi-asserted-by":"publisher","first-page":"E635","DOI":"10.1161\/STROKEAHA.121.035002","volume":"52","author":"A De Havenon","year":"2021","unstructured":"De Havenon A, et al. Cilostazol for secondary stroke prevention: history, evidence, limitations, and possibilities. Stroke. 2021;52(10):E635\u201345. https:\/\/doi.org\/10.1161\/STROKEAHA.121.035002.","journal-title":"Stroke"},{"issue":"11","key":"739_CR22","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jacc.2010.11.024","volume":"57","author":"ER Bates","year":"2011","unstructured":"Bates ER, Lau WC, Angiolillo DJ. Clopidogrel\u2013drug interactions. J Am Coll Cardiol. 2011;57(11):1251\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2010.11.024.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"739_CR23","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1161\/01.str.0000022808.21776.bf","volume":"33","author":"C Weimar","year":"2002","unstructured":"Weimar C, et al. Assessment of functioning and disability after ischemic stroke. Stroke. 2002;33(8):2053\u20139. https:\/\/doi.org\/10.1161\/01.str.0000022808.21776.bf.","journal-title":"Stroke"},{"issue":"1","key":"739_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40263-024-01127-7","volume":"39","author":"S Rezk","year":"2024","unstructured":"Rezk S, Nevine A, Nahas E, Fouad M, Khalil E, Elbassiouny A. TICA-CLOP STUDY: ticagrelor versus clopidogrel in acute moderate and moderate-to-severe ischemic stroke, a randomized controlled multi-center trial. CNS Drugs. 2024;39(1):81\u201393. https:\/\/doi.org\/10.1007\/s40263-024-01127-7.","journal-title":"CNS Drugs"},{"issue":"4","key":"739_CR25","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1161\/STROKEAHA.120.032060","volume":"52","author":"GM De Marchis","year":"2021","unstructured":"De Marchis GM, et al. New avenues for optimal treatment of atrial fibrillation and stroke prevention. Stroke. 2021;52(4):1490\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.120.032060.","journal-title":"Stroke"},{"issue":"3","key":"739_CR26","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s13760-024-02499-9","volume":"124","author":"S Elgamal","year":"2024","unstructured":"Elgamal S, Ahmed SR, Nahas MM, Hendawy SR, Elshafei O, Zeinhom MG. The effect of lacosamide on calcitonin gene-related peptide serum level in episodic migraine patients: a randomized, controlled trial. Acta Neurol Belg. 2024;124(3):965\u201372. https:\/\/doi.org\/10.1007\/s13760-024-02499-9.","journal-title":"Acta Neurol Belg"},{"issue":"6","key":"739_CR27","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334\u201357. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15026.","journal-title":"Hypertension"},{"issue":"13","key":"739_CR28","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1212\/WNL.0000000000001972","volume":"85","author":"L Liu","year":"2015","unstructured":"Liu L, et al. Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology. 2015;85(13):1154\u201362.","journal-title":"Neurology"},{"key":"739_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010603","author":"TH Park","year":"2020","unstructured":"Park TH, et al. Neurologic deterioration in patients with acute ischemic stroke or transient ischemic attack. Neurology. 2020. https:\/\/doi.org\/10.1212\/WNL.0000000000010603.","journal-title":"Neurology"},{"issue":"1","key":"739_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman S, Anger SU, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202\u20134. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03678.x.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"739_CR31","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1161\/01.STR.0000018645.04200.7D","volume":"33","author":"AJ Furlan","year":"2002","unstructured":"Furlan AJ. Acute stroke trials: strengthening the underpowered. Stroke. 2002;33(6):1450\u20131. https:\/\/doi.org\/10.1161\/01.STR.0000018645.04200.7D.","journal-title":"Stroke"},{"issue":"21","key":"739_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.123.031611","volume":"12","author":"C Wang","year":"2023","unstructured":"Wang C, et al. Ticagrelor versus clopidogrel in minor stroke or transient ischemic attack with intracranial artery stenosis: a post hoc analysis of CHANCE-2. J Am Heart Assoc. 2023;12(21):1\u201312. https:\/\/doi.org\/10.1161\/JAHA.123.031611.","journal-title":"J Am Heart Assoc"},{"issue":"2\u20133","key":"739_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000097042","volume":"23","author":"M K\u00f6hrmann","year":"2007","unstructured":"K\u00f6hrmann M, Schellinger PD. Symptomatic intracranial hemorrhage after thrombolysis. Cerebrovasc Dis (Basel, Switzerland). 2007;23(2\u20133):83\u20134. https:\/\/doi.org\/10.1159\/000097042.","journal-title":"Cerebrovasc Dis (Basel, Switzerland)"},{"issue":"11","key":"739_CR34","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1105335","volume":"365","author":"MI Chimowitz","year":"2011","unstructured":"Chimowitz MI, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa1105335.","journal-title":"N Engl J Med"},{"issue":"4","key":"739_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1053\/jscd.2000.7216","volume":"9","author":"F Gotoh","year":"2000","unstructured":"Gotoh F, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. 2000;9(4):147\u201357. https:\/\/doi.org\/10.1053\/jscd.2000.7216.","journal-title":"J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc"},{"issue":"21","key":"739_CR36","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1016\/0006-2952(84)90103-5","volume":"33","author":"H Umekawa","year":"1984","unstructured":"Umekawa H, Tanaka T, Kimura Y, Hidaka H. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography. Biochem Pharmacol. 1984;33(21):3339\u201344. https:\/\/doi.org\/10.1016\/0006-2952(84)90103-5.","journal-title":"Biochem Pharmacol"},{"issue":"25","key":"739_CR37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/s0024-3205(97)00986-7","volume":"61","author":"N Minami","year":"1997","unstructured":"Minami N, et al. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci. 1997;61(25):383\u20139. https:\/\/doi.org\/10.1016\/s0024-3205(97)00986-7.","journal-title":"Life Sci"},{"issue":"4","key":"739_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/0049-3848(90)90079-r","volume":"57","author":"T Igawa","year":"1990","unstructured":"Igawa T, et al. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res. 1990;57(4):617\u201323. https:\/\/doi.org\/10.1016\/0049-3848(90)90079-r.","journal-title":"Thromb Res"},{"issue":"Suppl 1","key":"739_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ijs.12460","volume":"10","author":"JS Kim","year":"2015","unstructured":"Kim JS, Kwon SU, Uchiyama S. Cilostazol research in Asia: can it be applied to European and American patients? Int J Stroke Off J Int Stroke Soc. 2015;10(Suppl 1):1\u20139. https:\/\/doi.org\/10.1111\/ijs.12460.","journal-title":"Int J Stroke Off J Int Stroke Soc"},{"key":"739_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000158","author":"WJ Powers","year":"2018","unstructured":"Powers WJ, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2018. https:\/\/doi.org\/10.1161\/STR.0000000000000158.","journal-title":"Stroke"},{"issue":"3","key":"739_CR41","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4103\/aian.AIAN_228_17","volume":"21","author":"V Chenna","year":"2018","unstructured":"Chenna V, et al. Predictors of intracerebral hemorrhage in acute stroke patients receiving intravenous recombinant tissue plasminogen activator. Ann Indian Acad Neurol. 2018;21(3):214\u20139. https:\/\/doi.org\/10.4103\/aian.AIAN_228_17.","journal-title":"Ann Indian Acad Neurol"},{"issue":"8","key":"739_CR42","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/ijs.12626","volume":"10","author":"T Dor\u0148\u00e1k","year":"2015","unstructured":"Dor\u0148\u00e1k T, et al. Posterior vs. anterior circulation infarction: demography, outcomes, and frequency of hemorrhage after thrombolysis. Int J Stroke. 2015;10(8):1224\u20138. https:\/\/doi.org\/10.1111\/ijs.12626.","journal-title":"Int J Stroke"},{"issue":"November","key":"739_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2020.551157","volume":"11","author":"F Sun","year":"2020","unstructured":"Sun F, et al. Predictive factors of hemorrhage after thrombolysis in patients with acute ischemic stroke. Front Neurol. 2020;11(November):1\u20136. https:\/\/doi.org\/10.3389\/fneur.2020.551157.","journal-title":"Front Neurol"},{"issue":"1","key":"739_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-021-02534-9","volume":"22","author":"Y Xue","year":"2022","unstructured":"Xue Y, et al. Predictors for symptomatic intracranial hemorrhage after intravenous thrombolysis with acute ischemic stroke within 6 h in northern China: a multicenter, retrospective study. BMC Neurol. 2022;22(1):1\u20137. https:\/\/doi.org\/10.1186\/s12883-021-02534-9.","journal-title":"BMC Neurol"},{"issue":"1\u20132","key":"739_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jns.2013.01.029","volume":"327","author":"J Aoki","year":"2013","unstructured":"Aoki J, et al. NIHSS-time score easily predicts outcomes in rt-PA patients: the SAMURAI rt-PA registry. J Neurol Sci. 2013;327(1\u20132):6\u201311. https:\/\/doi.org\/10.1016\/j.jns.2013.01.029.","journal-title":"J Neurol Sci"},{"key":"739_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s41983-019-0110-y","author":"MA Elsayed","year":"2019","unstructured":"Elsayed MA, Salah H, Sabbah A, Hatem G, Moawad MK. Early functional outcome after IV rTPA administration in Egyptian acute ischemic stroke patients. Egypt J Neurol Psychiatry Neurosurg. 2019. https:\/\/doi.org\/10.1186\/s41983-019-0110-y.","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"issue":"1","key":"739_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/nejmoa1603060","volume":"375","author":"SC Johnston","year":"2016","unstructured":"Johnston SC, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375(1):35\u201343. https:\/\/doi.org\/10.1056\/nejmoa1603060.","journal-title":"N Engl J Med"},{"issue":"27","key":"739_CR48","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1056\/nejmoa2111749","volume":"385","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N Engl J Med. 2021;385(27):2520\u201330. https:\/\/doi.org\/10.1056\/nejmoa2111749.","journal-title":"N Engl J Med"},{"issue":"3","key":"739_CR49","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.3892\/mmr.2018.8377","volume":"17","author":"M Dehbozorgi","year":"2018","unstructured":"Dehbozorgi M, et al. Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (-806 C>T) alleles among an Iranian population of different ethnicities. Mol Med Rep. 2018;17(3):4195\u2013202. https:\/\/doi.org\/10.3892\/mmr.2018.8377.","journal-title":"Mol Med Rep"},{"issue":"1","key":"739_CR50","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s11033-024-10093-8","volume":"51","author":"M Messaoudi","year":"2024","unstructured":"Messaoudi M, Pakstis AJ, Boussetta S, Ben Ammar Elgaaied A, Kidd KK, Cherni L. CYP2C gene polymorphisms in North African populations. Mol Biol Rep. 2024;51(1):1145. https:\/\/doi.org\/10.1007\/s11033-024-10093-8.","journal-title":"Mol Biol Rep"},{"issue":"13","key":"739_CR51","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1212\/WNL.0000000000001972","volume":"85","author":"L Liu","year":"2015","unstructured":"Liu L, et al. Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology. 2015;85(13):1154\u201362. https:\/\/doi.org\/10.1212\/WNL.0000000000001972.","journal-title":"Neurology"},{"issue":"8","key":"739_CR52","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.5551\/jat.63632","volume":"30","author":"H Liu","year":"2023","unstructured":"Liu H, et al. Comparison of cilostazol versus clopidogrel in addition to aspirin in patients with ischemic stroke who underwent intracranial or extracranial artery stent implantation. J Atheroscler Thromb. 2023;30(8):1010\u201321. https:\/\/doi.org\/10.5551\/jat.63632.","journal-title":"J Atheroscler Thromb"},{"issue":"10","key":"739_CR53","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1161\/STROKEAHA.110.609370","volume":"42","author":"SU Kwon","year":"2011","unstructured":"Kwon SU, et al. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke. 2011;42(10):2883\u201390. https:\/\/doi.org\/10.1161\/STROKEAHA.110.609370.","journal-title":"Stroke"},{"key":"739_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2040622320936418","volume":"11","author":"TH Lee","year":"2020","unstructured":"Lee TH, Lin YS, Liou CW, Der Lee J, Peng TI, Liu CH. Comparison of long-term efficacy and safety between cilostazol and clopidogrel in chronic ischemic stroke: a nationwide cohort study. Ther Adv Chronic Dis. 2020;11:1\u201314. https:\/\/doi.org\/10.1177\/2040622320936418.","journal-title":"Ther Adv Chronic Dis"},{"issue":"8","key":"739_CR55","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00228-023-03522-3","volume":"79","author":"YJ Lee","year":"2023","unstructured":"Lee YJ, Je NK. Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. Eur J Clin Pharmacol. 2023;79(8):1107\u201316. https:\/\/doi.org\/10.1007\/s00228-023-03522-3.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"739_CR56","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.atherosclerosissup.2005.09.002","volume":"6","author":"S Goto","year":"2005","unstructured":"Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005;6(4):3\u201311. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2005.09.002.","journal-title":"Atheroscler Suppl"},{"issue":"4","key":"739_CR57","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/s0741-5214(03)01029-2","volume":"38","author":"DB Wilhite","year":"2003","unstructured":"Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg. 2003;38(4):710\u20133. https:\/\/doi.org\/10.1016\/s0741-5214(03)01029-2.","journal-title":"J Vasc Surg"},{"issue":"5","key":"739_CR58","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000022512","volume":"29","author":"Y Tamai","year":"1999","unstructured":"Tamai Y, Takami H, Nakahata R, Ono F, Munakata A. Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis. 1999;29(5):269\u201376. https:\/\/doi.org\/10.1159\/000022512.","journal-title":"Haemostasis"},{"issue":"1","key":"739_CR59","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1046\/j.1365-2141.2000.02039.x","volume":"110","author":"P de Moerloose","year":"2000","unstructured":"de Moerloose P, Reber G, Perrier A, Perneger T, Bounameaux H. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. Br J Haematol. 2000;110(1):125\u20139. https:\/\/doi.org\/10.1046\/j.1365-2141.2000.02039.x.","journal-title":"Br J Haematol"},{"issue":"4","key":"739_CR60","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/01.str.31.4.817","volume":"31","author":"T Yamaguchi","year":"2000","unstructured":"Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation\u202f: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke. 2000;31(4):817\u201321. https:\/\/doi.org\/10.1161\/01.str.31.4.817.","journal-title":"Stroke"},{"issue":"4","key":"739_CR61","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/s0735-1097(01)01587-x","volume":"38","author":"V Fuster","year":"2001","unstructured":"Fuster V, et al. ACC\/AHA\/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee. J Am Coll Cardiol. 2001;38(4):1231\u201366. https:\/\/doi.org\/10.1016\/s0735-1097(01)01587-x.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"739_CR62","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.3892\/mmr.2016.4881","volume":"13","author":"M-Q Shi","year":"2016","unstructured":"Shi M-Q, et al. Cilostazol suppresses angiotensin II-induced apoptosis in endothelial cells. Mol Med Rep. 2016;13(3):2597\u2013605. https:\/\/doi.org\/10.3892\/mmr.2016.4881.","journal-title":"Mol Med Rep"},{"issue":"3","key":"739_CR63","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/nejmoa1916870","volume":"383","author":"SC Johnston","year":"2020","unstructured":"Johnston SC, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383(3):207\u201317. https:\/\/doi.org\/10.1056\/nejmoa1916870.","journal-title":"N Engl J Med"},{"issue":"3","key":"739_CR64","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/nejmoa1800410","volume":"379","author":"SC Johnston","year":"2018","unstructured":"Johnston SC, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379(3):215\u201325. https:\/\/doi.org\/10.1056\/nejmoa1800410.","journal-title":"N Engl J Med"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00739-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00739-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00739-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:58:22Z","timestamp":1747663102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00739-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00739-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Mohamed G. Zeinhom, Dr. Mohamed Ismaiel, Dr. Mohamed Fouad elsayed Khalil, Dr. Mohamed Ahmed Almoataz, Dr. Tarek youssif omar, Dr. Ahmed Mohamed ali Daabis, Dr. Hossam Mohamed Refat, Dr. Ahmed ahmed Mohamed kamal ebied, Dr. Noha Abdelwahed, Dr. Ahmed Zaki Omar Akl, Dr. Emad Labib Abdelhamid Mahmoud, Dr. Salah Ibrahim Ahmed, Dr. Sherihan Rezk Ahmed have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Our study was approved by the ethical committee of Kafr El-sheikh University (reference number KFSIRB200-145). We obtained formal written consent from the patients or their first of kin if the patients were illiterate or critically ill. The data reported herein do not contain any identifiable information regarding our patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}